Recently, it has been reported that prophylactic administration of ciprofloxacin during cyclophosphamide (CY) conditioning was a high-risk factor for relapse in patients undergoing allogeneic BMT. In the present study, we investigated the possible mechanisms of this interaction in male Sprague-Dawley rats. The kinetics of CY and its active 4-OH-CY metabolite were determined, after 3 days pretreatment with ciprofloxacin (200 mg/kg) and compared to control rats without treatment. CY was administered as a high or low single intravenous dose (150 and 90 mg/kg, respectively). The expression of the CYP2B1, CYP2B2, CYP2C11, CYP3A1 and CYP3A2 genes was evaluated by SYBR Green I Dye real-time PCR for quantification of mRNA. The administration of ciprofloxacin resulted in a significant increase in the AUC (P ¼ 0.007) and a significant decrease in clearance (P ¼ 0.007) when CY was given as a high dose. In accordance, the metabolic ratio (AUC4-OH-CY/ AUCCY) was significantly lower (P ¼ 0.007) compared to that found in the control group. Ciprofloxacin significantly suppressed gene expression of CYP2C11 (P ¼ 0.01) and CYP3A1 (P ¼ 0.04); however, no effect was observed on the gene expression of CYP3A2, CYP2B1 and CYP2B2. Our study revealed that ciprofloxacin interacts with CY and suppressed relevant cytochromes P450 at the transcriptional level. This study may have a great clinical impact when ciprofloxacin is used in therapy. An alternative but minor pathway is the inactivation of CY and both pathways are dependent on cytochrome P450 enzymes. [2] [3] [4] [5] In humans, CYP2B6 is the main catalyst of CY activation, along with the contribution from CYP2C, CYP3A4, and CYP2A6 isoenzymes.
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An alternative but minor pathway is the inactivation of CY and both pathways are dependent on cytochrome P450 enzymes. [2] [3] [4] [5] In humans, CYP2B6 is the main catalyst of CY activation, along with the contribution from CYP2C, CYP3A4, and CYP2A6 isoenzymes. [5] [6] [7] CY inactivation is mostly catalysed by CYP3A4. 5 In noninduced male rats, the constitutively expressed CYP2C11 and CYP3A2 are the major enzymes involved in CY bioactivation, while the inducible CYP2B1 was shown to be a major catalyst of CY activation in induced rats. 2, 4 Thus, in vivo or in vitro alteration of hepatic CYPs could change the rate and pattern of CY metabolism. 8 Concomitant use of CY with other drugs that are inhibitors or inducers of CYP2B, CYP2C, or CYP3A enzymes could cause interactions. [9] [10] [11] [12] Ciprofloxacin is a DNA gyrase inhibitor used as an antibacterial drug. 13 This fluoroquinolone agent has gained widespread use in the treatment of a broad range of infections.
14 Investigations focused on drug interactions between ciprofloxacin and other drugs have been reported in recent years. Particularly, interactions between ciprofloxacin and drugs metabolised by the hepatic cytochrome P450 (CYP) system have attracted attention. 15 Studies with hepatic microsomes demonstrated that ciprofloxacin can decrease CYP3A-mediated biotransformation in man and rat by competitive inhibition. 16 Pharmacokinetic interaction between cyclosporine and ciprofloxacin has been established in vivo and in vitro. 17 It was also shown that ciprofloxacin is an inhibitor of cytochrome P4501A2 activity in vitro and in vivo. 18 Interactions between ciprofloxacin and theophylline 19, 20 or caffiene 18 have been identified. In addition, adverse reaction of CYP-metabolized warfarin was reported because of coadministration of fluoroquinolone agents. 21 A study that might reflect ciprofloxacin-CY interaction was recently published. 22 The 5-year probability of relapse in leukaemia patients receiving ciprofloxacin prophylaxis during CY conditioning prior to allogeneic BMT was 40%, compared to 24% in patients who did not receive ciprofloxacin. Since the graft-versus-leukaemia (GVL) effect did not seem to be affected by ciprofloxacin, it was postulated that ciprofloxacin might interfere with the metabolism of CY. Potentially, a reduction in the levels of the active CY metabolite could hamper the immunosuppressive and the antileukaemic effect of the drug, thereby increasing the risk of recurrent disease.
Based on this report, we designed the present study in a rat model in order to investigate: (1) the influence of ciprofloxacin on CY pharmacokinetics and (2) the effects of ciprofloxacin on hepatic CYP mRNA expression.
Materials and methods

Drugs and chemicals
Ciprofloxacin granulate 100 mg/ml was purchased from Bayer AG (Leverkusen, Germany). Cyclophosphamide was purchased from Sigma Chemical CO (St Louis, USA). Ifosfamide (holoxan) and 4-OH-cyclophosphamide, were obtained from Asta Medica (Frankfurt am Main, Germany). Hypnorm (0.315 mg/ml fentanyl citrate eqvivalent to 0.2 mg fenthanyl base) was purchased from JanssenPharma (Beerse, Belgium). Acetic acid ethyl ester was obtained from Sigma Aldrich (Steinheim, Germany) and acetonitrile from Fisher Scientific (Leicestershire, UK). KH 2 PO 4 was purchased from MERCK (Darmstadt, Germany). CYP2B primers were purchased from Cybergene AB, Sweden. CYP2C and CYP3A primers were purchased from DAN Tecknology, Denmark.
Animals
Sprague-Dawley male rats 6-week-old (B&K Universal, Sollentuna, Sweden) were housed in cages, six animals in each, and fed ad libitum. The room temperature was maintained at 221C with a 12-h light-dark cycle. The average body weight of the rats on arrival was 180 g. The Animal Care Committee at Karolinska Institute approved all experimental protocols used in the study. The experiment was designed according to the guidelines established by the Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources.
Treatment of animals
Rats were divided into two groups according to the treatment schedule. Group A received low-dose CY (90 mg/kg) that is a clinical relevant dose of 30 mg/kg, while group B was given high-dose CY (150 mg/kg), which is close to the high dose used in BMT conditioning. Each group was divided into two subgroups: A1, A2 and B1, B2. Both groups A1 and B1 were pretreated with ciprofloxacin (200 mg/kg) by gastric tube, once daily for 3 days, prior to CY administration, while group A2 and B2 received only CY as a control. CY (30 mg/ml) was dissolved in physiological saline and injected i.v. in the tail vein after the last dose of ciprofloxacin. Rats were anaesthetised with 0.15 ml hypnorm, and 3-4 ml blood samples were drawn via heart puncture at 0 (control); 0.17, 0.3, 0.5, 1, 2, 3, 4, 6, 8 and 16 h after CY administration. Each time point contained two rats. The samples were immediately centrifuged at 3000 rpm at 41C for 5 min. A volume of 0.5 ml of plasma was mixed for approximately 10 s with 1 ml cold acetonitrile, centrifuged for 5 min at 3000 rpm and the clear supernatant was recovered and stored at À701C until analysis of 4-OH-CY. The remaining plasma was stored at À701C until analysis of CY. At the 0 time point, seven rats treated with ciprofloxacin and six drug-free control rats were killed and their livers removed, and kept at À701C for subsequent total RNA isolation.
Quantification of cyclophosphamide by high-performance liquid chromatography (HPLC)
A measure of 1 ml of plasma was spiked with 25 ml internal standard (IS) (1 mg/ml ifosfamide diluted in water). The samples were extracted in 5 ml acetic acid ethyl ester, vortexed for 15 s at room temperature and then centrifuged at 4000 rpm at room temperature for 10 min. The organic layer was evaporated to dryness at 371C under a stream of nitrogen. The residue was dissolved in 100 ml of mobile phase (acetonitrile : 0.5 M KH 2 PO 4 buffer, 12 : 88 v/v). Samples were put in an ultrasound bath for 15 s. A volume of 50 ml of sample was injected into an HPLC system, which consisted of a Jasco PU 980 pump unit and a CMA/240 automatic injector with a 100 ml sample loop. A UV detector, Milton Roy Spectro Monitor 3100 was used at a wavelength of 195 nm. The analysis was performed using a Chrompack 100 Â 4.6 mm microsphere C18 column with a guard column, Waters Millipore RCSS Guard-PAKt Bondpakt C18. The mobile phase consisted of acetonitrile and 0.05 M KH 2 PO 4 buffer (12 : 88 v/v) and the flow rate was set to 1.3 ml/min. Under these conditions, the retention times were 19 and 22 min for ifosfamide and CY, respectively. Standard curve was conducted using blank plasma spiked with increasing concentrations of CY. Calibration curves were linear within the range of 1-200 mg/ml. Quality control samples were included routinely at each run and were diluted in blank plasma to a concentration of 7.5 and 75 mg/ml CY, including IS, and frozen at À201C.
Quantification of 4-OH-cyclophosphamide by HPLC
Quantification of 4-OH-CY was performed as recently described. 23 Briefly, 4-OH-CY was stabilised by adding dansylhydrazone and hydrochloric acid. The mixture was vortexed for 15 s, followed by 5 min incubation at 501C in water bath. Final sample of 100 ml was injected into the HPLC system, consisting of a Gilson 234 (Middleton, WI, USA) injector, a 200 ml loop and a Shimadzu LC10AD (Kyoto, Japan) solvent delivery system. The SHIMADZU RF-551 (Kyoto, Japan) spectrofluorometric detector was set at an excitation wavelength of 350 nm and emission wavelength of 550 nm. The mobile phase consisted of phosphate buffer, pH 3.5 (m ¼ 0.2)/acetonitrile (2:1 v/v). The flow rate was 2 ml/min at ambient room temperature. A standard curve was analysed by dissolving 4-OH-CY in plasma in the concentration range of 0.01-20 mg/ml using the same assay as described above.
Extraction of RNA and cDNA synthesis
Total RNA was isolated from the rat livers with QuickPrep s Total RNA Extraction Kit (Amersham Pharmacia Biotech, USA). The concentration and the purity of RNA were determined by measuring the absorbance at 260 and 280 nm with correction for background at 320 nm in a spectrophotometer (Beckman DU s 530 Life Science UV/Vis). RNA samples were stored at À801C or processed directly by reverse transcription using the First-strand cDNA Synthesis Kit (Amersham Pharmacia Biotech, UK). An amount of 1 mg total RNA was used to produce cDNA in a total volume of 15 ml. The reaction was incubated at 371C for 1 h, using oligo(dT)18 as the primer for reverse transcription, and heat denatured at 951C for 5 min. cDNA samples were further diluted 10 times in water before being used immediately for PCR, or stored at À801C.
RT-PCR test
The primers used for CYP2B1, CYP2B2, CYP2C11, CYP3A1 and CYP3A2 specific PCR amplification are given in Table 1 . 24, 25 The PCR conditions were optimised to produce a pure PCR product with a minimum background. PCR was carried out in a final volume of 25 ml containing 33 ng cDNA, 2.5 ml 10 Â PCR buffer (Mg 2+ free), 1.5 mM MgCl 2 , 0.2 M dNTP, 0.5 mm forward and reverse primers, and 0.5 U AmpliTaq DNA Polymerase (Applied Biosystems, Foster City, CA, USA). PCR was performed in a GeneAMP s PCR system 9700 (Applied Biosystems, Foster City, CA, USA). The image was scanned and photographed using a Bio-RAD s CHEMI DOC UV camera (USA), and data analysed using the Quantity One software, Version 4.1.
SYBR Green I dye real-time PCR
Real-time quantitative PCR was performed for the assessment of the specific mRNAs and was performed in an ABI Prism 7700 machine (Applied Biosystems, Foster City, CA, USA) after previous RT-PCR test step. SYBR s Green I dye was used to detect double-stranded cDNA generated during the PCR amplification. The quantitative PCR was monitored by measuring the increase in fluorescence by the binding of SYBR Green I dye to the double-stranded cDNA. SYBR Green PCR master Mix (P/N 4309155) was purchased from Applied Biosystems (Foster City, CA, USA), containing AmpliTaq Gold s DNA Polymerase and optimised buffer components. A fraction of 5 ml of cDNA and 0.5 mM of primers were added to SYBR Green master mix to make a final 25 ml reaction volume.
Cycling conditions for RT-PCR was also used for the real-time PCR (Table 1) . Nonspecific amplification was checked for by analysis of the PCR amplification products by agarose gel electrophoresis (Figure 1) .
Dilutions of a cDNA sample prepared from a liver was used to construct the relative standard curves, given that it has 10 000 copies mRNA per reaction (equal to 33 ng total RNA). Since between CYP2B1 and 2B2 as well as CYP3A1 and 3A2 reverse primers had only 2-3 base pair mismatches, we could therefore use three relative standard curves for quantifying five CYP enzymes. mRNA (18 s) was used as housekeeping gene, for normalisation of cDNA input in each PCR. A ratio of 1 : 100 dilution of each cDNA sample was used for 18 s PCR. Results of specific CYP mRNAs were presented as a copy number based CYP/18 s ratio.
Pharmacokinetic and statistical methods
CY and its metabolite 4-OH-CY concentration-time data were adjusted to a two-compartment open model using Gauss-Newton (Levenberg-Hartly) criteria. Parameters such as the volume of distribution in the central compartment, the elimination rate constant, the maximum plasma concentration (C max ) and the microconstants were estimated. Whereas, the clearance (CL), volume of distribution at the steady state (V d ) and mean residence time were calculated from the primary parameters. The plasma concentration vs time (AUC) was calculated from the model-derived parameters and the elimination half-lives (t 1/2 ) were calculated from the slope of the terminal phase of elimination. The pharmacokinetic modelling was performed using WinNonlin version 3.0 (Pharsight, Mountain View, CA, USA). The mean, median and standard deviations were calculated using GraphPad, InStat (version 3.0, Graph Pad, San Diego, USA). Statistical analysis was performed using Mann-Whitney's U-test to compare the two groups.
Results
Gene expression of specific rat CYPs
The real-time PCR was performed in duplicate for each rat cDNA sample. The mean coefficient of variation (CV) of the Ct (the fractional PCR cycle number at which the fluorescence passes the fixed threshold) values was 0.44% for 115 pairs of PCR samples. The CV within each standard was less than 0.5%. Ct values of each CYP mRNA expressed in drug-free rat livers (n ¼ 6), the arbitrary unit of real-time PCR quantity, were as follows: CYP2C11 (15.170. 
Effect of ciprofloxacin on CYP gene expression
By comparison of the mean specific mRNA quantity between ciprofloxacin-treated (n ¼ 7) and control (n ¼ 6) groups, it was observed that pretreatment with ciprofloxacin significantly suppressed gene expression of CYP2C11 (P ¼ 0.01) and CYP3A1 (P ¼ 0.04) (Figure 2 ). However, no significant effect on CYP2B1 (P ¼ 0.29), CYP2B2 (P ¼ 0.63) or CYP3A2 (P ¼ 0.84) was observed.
Ciprofloxacin effects on CY kinetics
Plasma concentrations of CY and 4-OH CY at each time point were measured, and the concentration vs time curves ( Figure 3) were conducted as described in the Materials and Methods. Treatment with ciprofloxacin has significantly increased the AUC of CY at the higher dose (P ¼ 0.007, Table 2 ). Consistent with this, the total clearance of CY was decreased (P ¼ 0.007) and the metabolic ratio (AUC 4ÀOHÀCY /AUC CY ) was lower compared to that observed in the control group (P ¼ 0.007, Figure 4 ). At the low CY dose, the metabolic ratio in ciprofloxacin- treated rats tended to be lower than in the control group, although it did not reach statistical significance (P ¼ 0.14). No effect of ciprofloxacin on 4-OH-CY kinetics was observed at either CY concentration.
Discussion
Cyclophosphamide is widely used in the clinic as a chemotherapeutic drug for treatment of different malignancies. Its immunosuppressive property makes it applicable in autoimmune diseases and is increasingly used in organ transplantation protocols. 1, 26 In hospitalised patients, CY is often combined with other drugs. 17, 22, 27 CY is a prodrug, which has to be activated to exert its cytotoxic effect. The activation and the deactivation of CY mainly involves the hepatic CYP enzymes. Since both the alternative metabolic pathways are CYP dependent, [1] [2] [3] 6, 7 many enzyme inhibitors and inducers might alter the pharmacokinetics and hence the therapeutic efficacy of CY. 8, 27 Concomitant administration of CY and ciprofloxacin is an example that resulted in unfavourable clinical outcome, as reported 22 previously. Between 1986 and 1993, 153 adult patients received ciprofloxacin continuously for Gram-negative prophylaxis during CY conditioning. After 1993, ciprofloxacin was given only after CY treatment (n ¼ 103). The authors reported increased relapse risk for those patients who were treated concomitantly with ciprofloxacin during CY therapy compared to patients who received their ciprofloxacin after CY. 22 Our results clearly show an interaction between ciprofloxacin and CY metabolism. At high CY dose, the AUC of CY was lower in the ciprofloxacin-treated groups of animals compared to control group. However, no significant difference was observed comparing the AUC of 4-OH-CY. At low CY dose, no significant differences were observed between ciprofloxacin-treated animals and controls. Regarding the CY cytotoxicity, an important measure is the exposure to 4-OH-CY, which can determine both tumour response and adverse effects. Since 4-OH-CY is known to be formation limited, many authors express 4-OH-CY exposure as the ratio between the CY AUC and the 4-OH-CY AUC. Slattery et al 28 have reported a negative correlation between CY AUC and 4-OH-CY AUC in patients undergoing bone marrow transplantation, receiving busulphan and total body irradiation. Ayash et al 29 have also found an inverse correlation between cardiac toxicity and tumour response and CY AUC in breast cancer patients treated with high-dose cyclophosphamide, thiotepa and carboplatin. Both authors suggested that lower CY AUC might correlate with an increase in conversion of CY to its cytotoxic metabolite 4-OH-CY. In contrast, Sladek et al 30, 31 have concluded that the amount of 4-OH-CY should be constant according to the rate with which 4-OH-CY is formed from CY, which was also observed in our study.
In our investigation, the metabolic ratio (AUC 4ÀOHÀCY / AUC CY ) was significantly lower in animals treated with ciprofloxacin compared with control animals at high CY dosage. At the low CY dose, however, the clearance and metabolic ratio in ciprofloxacin-treated animals were generally lower, but without reaching the significant level. Regarding the alteration of CY kinetics by ciprofloxacin, the difference between the high and low CY dose could be explained by the relevant CYP enzyme capacity, which would be the limiting factor for CY metabolite formation at high dose, but not necessarily at low dose. Apparently, ciprofloxacin inhibited the CYPmediated CY biotransformation in rats at high dosage. It is most likely that a similar reduction in the metabolic ratio and a decrease in the levels of active 4-OH-CY can be expected in patients, who have received ciprofloxacin prophylactic treatment prior to CY conditioning before BMT. As a result, the immunosuppressive effect of CY may be hampered by ciprofloxacin, which is detrimental to the treatment. As a long-term adverse effect, coadministration of ciprofloxacin may result in an increased risk of recurrent disease. This is, the first in vivo study showing the drug interaction between cyclophos-phamide and ciprofloxacin.
Fluoroquinolones are important antimicrobial drugs in the therapy owing to their broad antibacterial spectrum, high bioavailability, safe profile and favourable pharmacokinetics. 13, 14 Many interactions between ciprofloxacin and other drugs, metabolised by hepatic cytochrome P450 isoenzymes, have been identified. [15] [16] [17] 20, 21, 32 Thus, it has been established that ciprofloxacin is an inhibitor of cytochrome P450 3A2 activity in vitro and in vivo. [16] [17] [18] [19] [20] Since CYP3A2 is involved in both pathways, that is, activation and deactivation of CY, a decreased clearance and subsequently a decreased metabolic ratio (AUC 4ÀOHÀCY /AUC CY ) caused by ciprofloxacin would be expected.
In the present investigation, we found that 3 days pretreatment with ciprofloxacin significantly decreased CYP2C11 and CYP3A1 gene expression at mRNA level. This finding, in combination with the observed alteration of CY kinetics caused by ciprofloxacin, might explain some of the mechanisms underlying the interaction between cyclophosphamide and ciprofloxacin at the gene expression level. To our knowledge this is the first study to explain the interaction between ciprofloxacin and cyclophosphamide on the gene expression level.
In conclusion, co-administration of drugs that inhibit or induce specific cytochrome enzymes must be avoided especially during treatment with CY, since they might affect the CYP-mediated CY activation. The drug interaction between cyclophosphamide and ciprofloxacin shown in the present study may explain the unfavourable clinical outcome that was observed in patients. Furthermore, our study adds more information to the mechanisms behind the CY-ciprofloxacin interaction.
